Table 5 Resistance prevalence of eight common bacteria, U.S. (all patients pooled), 1999–2002
From: Antibiotic resistance as a global threat: Evidence from China, Kuwait and the United States
unit: % | ||||||||
|---|---|---|---|---|---|---|---|---|
Bacterium | Resistant to antibiotic(s) | 1999 | 2000 | 2001 | 2002 | Average Resistance | Average Growth Rate | |
PAE | Ciprofloxacin/ofloxacin | 23 | 25 | 28 | 29 | 26 | 8 | |
Levofloxacin | 29 | 30 | 31 | 30 | 30 | 1 | ||
Imipenem | 12 | 12 | 15 | 13 | 13 | 4 | ||
Ceftazidime | 8 | 8 | 9 | 9 | 9 | 4 | ||
Piperacillin | 10 | 10 | 11 | 12 | 11 | 6 | ||
SAU (MRSA) | Methicillin | 32 | 35 | 38 | 39 | 36 | 7 | |
Enterococcus spp | Vancomycin | 11 | 8 | 10 | 10 | 10 | -1 | |
ECO | Cef3 | 1 | 1 | 1 | 1 | 1 | 0 | |
Quinolone | 2 | 3 | 4 | 5 | 4 | 36 | ||
KPN | Cef3 | 4 | 4 | 4 | 5 | 4 | 8 | |
Enterobacter spp | Cef3 | 19 | 19 | 18 | 19 | 19 | 0 | |
Carbapenum | 1 | 1 | 1 | 1 | 1 | 0 | ||
CNS | Methicillin | 60 | 61 | 62 | 63 | 62 | 2 | |
Pneumococcus spp | Penicillin | 14 | 16 | 19 | 19 | 17 | 11 | |
Cef3 | 5 | 8 | 7 | 7 | 7 | 16 | ||
Mean: | 17 | 7 | ||||||